Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT Trial): A randomized, double-blind, placebo-controlled, two-stage study

HIV Clinical Trials

Volumn 14, Issue 6, 2013, Pages 261-273

  Macarthur, Rodger ^a   Hawkins, Trevor ^b   Brown, Stephen ^c   Lamarca, Anthony ^d   Clay, Patrick ^e   Barrett, Andrew ^f   Bortey, Enoch ^f   Paterson, Craig ^f   Golden, Pamela ^f   Forbes, William ^f  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Southwest CARE Center   (United States)

^c AIDS Research Alliance   (United States)

^d Therafirst Medical Center   (United States)

^e University of North Texas System College of Pharmacy   (United States)

^f Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

antidiarrheals; antiretroviral agents; chloride channels; diarrhea; drug toxicity; HIV; proanthocyanidins

Indexed keywords

CROFELEMER; PLACEBO;

ADULT; ARTICLE; CHRONIC DIARRHEA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FECES; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTESTINE MOTILITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ANTIDIARRHEALS; ANTIRETROVIRAL AGENTS; CHLORIDE CHANNELS; DIARRHEA; DRUG TOXICITY; HIV; PROANTHOCYANIDINS;

ADULT; CHLORIDE CHANNELS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROANTHOCYANIDINS;

EID: 84890485224     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1406-261     Document Type: Article

References (38)

1. Siddiqui U, Bini EJ, Chandarana K, et al. Prevalence and impact of diarrhea on health-related quality of life in HIVinfected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol. 2007;41(5): 484-490.
2. Tramarin A, Parise N, Campostrini S, et al. Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res. 2004;13(1): 243-250.
3. Burgoyne RW, Tan DH. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act. J Antimicrob Chemother. 2008;61(3): 469-473.
4. Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. Gastroenterology. 2009;136(6): 1952-1965.
5. MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012;55(6): 860-867.
6. Feasey NA, Healey P, Gordon MA. Review article: The aetiology, investigation and management of diarrhoea in the HIV-positive patient. Aliment Pharmacol Ther. 2011;34(6): 587-603.
7. Call SA, Heudebert G, Saag M, Wilcox CM. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol. 2000;95(11): 3142-3146.
8. Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2): 104-113.
9. Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis. 2004;39(5): 717-724.
10. daCosta diBonaventura M, Gupta S, Cho M, Mrus J. The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care. 2012;24(6): 744-755.
11. Hill A, Balkin A. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients. AIDS Rev. 2009;11(1): 30-38.
12. Prosperi MC, Fabbiani M, Fanti I, et al. Predictors of firstline antiretroviral therapy discontinuation due to drugrelated adverse events in HIV-infected patients: A retrospective cohort study. BMC Infect Dis. 2012;12: 296.
13. Sherr L, Lampe F, Norwood S, et al. Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS. 2007;18(10): 700-704.
14. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1): 57-65.
15. Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med. 2007;8(3): 186-191.
16. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4): 407-414.
17. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2(1): 38-45.
18. Harding R, Lampe FC, Norwood S, et al. Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect. 2010;86(7): 520-524.
19. Gupta R, Ordonez RM, Koenig S. Global impact of antiretroviral therapy-associated diarrhea. AIDS Patient Care STDS. 2012;26(12): 711-713.
20. Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDS. 2012;26(6): 312-319.
21. Edelman EJ, Gordon K, Justice AC. Patient and providerreported symptoms in the post-cART era. AIDS Behav. 2011;15(4): 853-861.
22. Nwachukwu CE, Okebe JU. Antimotility agents for chronic diarrhoea in people with HIV/AIDS. Cochrane Database Syst Rev. 2008;(4): CD005644.
23. Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest. 2003;111(7): 931-943.
24. Patel TS, Crutchley RD, Tucker AM, Cottreau J, Garey KW. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV AIDS (Auckl). 2013;5: 153-162.
25. Fischer H, Machen TE, Widdicombe JH, et al. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol. 2004;93 (2-3): 351-357.
26. Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010;77(1): 69-78.
27. Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010;44(5): 878-884.
28. Posch M, Koenig F, Branson M, Brannath W, Dunger- Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med. 2005;24(24): 3697-3714.
29. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Stat Med. 1999;18(14): 1833-1848.
30. Bardhan PK, Sharma ACB, Bolmall C, et al. Safety and efficacy of a novel anti-secretory anti-diarrheal agent crofelemer (NP-303) in the treatment of adult acute infectious diarrhea and cholera, with or without the use of antibiotics. Presented at: US-Japan Cooperative Medical Science Program 13th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim-Focused on Enteric Diseases;April 6-9, 2009;Kolkata, India.
31. DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol. 2002;97(10): 2585-2588.
32. Holodniy M, Koch J, Mistal M, et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol. 1999;94(11): 3267-3273.
33. Sherman DS, Fish DN. Management of protease inhibitorassociated diarrhea. Clin Infect Dis. 2000;30(6): 908-914.
34. Mannheimer SB, Wold N, Gardner EM, et al. Mild-tomoderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis. 2008;46(6): 941-945.
35. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: Review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42(6): 836-842.
36. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health;February 2013. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Accessed August 30, 2013.
37. Morpeth SC, Thielman NM. Diarrhea in patients with AIDS. Curr Treat Options Gastroenterol. 2006;9(1): 23-37.
38. Imodium A-D and Imodium multi-symptom relief (loperamide and loperamide-simethicone) [package insert]. Fort Washington, PA: McNeil Consumer Healthcare;2005.